GOLGA6L10 Inhibitors
GOLGA6L10 inhibitors encompass a variety of chemical compounds that interfere with the normal functioning of the Golgi apparatus and related cellular processes, ultimately leading to the inhibition of GOLGA6L10. Brefeldin A, for instance, undermines the structure and function of the Golgi by inhibiting ARF GTPases, critical in vesicle formation and trafficking, which are fundamental to the role of GOLGA6L10 in the Golgi apparatus. Similarly, Golgicide A and CID 1067700 target GBF1 and sec7 domain-containing proteins, respectively, both essential for maintaining Golgi structure and function. By impeding these proteins, the inhibitors indirectly affect the role of GOLGA6L10. Monensin alters Golgi pH and ion exchange, disturbing secretory pathways where GOLGA6L10 operates,and Tunicamycin causes ER stress that can lead to Golgi dysfunction, negatively influencing GOLGA6L10's associated processes. Disruption of cytoskeletal elements by Nocodazole, which impedes microtubule polymerization, also results in the mislocalization and subsequent dysfunction of GOLGA6L10 due to its reliance on an intact Golgi-microtubule network.
Dynasore and ILK inhibitor take a different approach by targeting endocytosis and integrin signaling, respectively, both of which are vital for the functional integrity of the Golgi apparatus and its associated proteins, including GOLGA6L10. The inhibition of dynamin by Dynasore affects vesicle trafficking, and the disruption of integrin signaling by the ILK inhibitor challenges the Golgi's architecture, indirectly inhibiting GOLGA6L10. Compounds like Betulinic acid and Swainsonine induce ER stress and inhibit glycosylation processes within the Golgi, leading to fragmentation and misprocessing that could compromise GOLGA6L10's function. Lastly, Retro-2cycl and Exo2, by inhibiting retrograde transport and the exocyst complex, respectively, exert their inhibitory effects on GOLGA6L10 by disrupting the trafficking and tethering of vesicles that are crucial for the maintenance of Golgi function, which is inherently tied to the proper operation of GOLGA6L10.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits ARF family GTPases by blocking the activation of ADP-ribosylation factors, which results in the disassembly of the Golgi apparatus. Since GOLGA6L10 is a Golgi-associated protein, its function is compromised when Golgi structure and trafficking are disrupted by this compound. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a polyether antibiotic that disrupts Golgi function by altering Golgi pH and cation exchange, leading to inhibition of secretory pathways. This affects the trafficking and processing functions where GOLGA6L10 is involved. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a potent inhibitor of the Golgi BFA resistance factor 1 (GBF1), which is essential for the maintenance of Golgi structure and function. Inhibition of GBF1 indirectly impedes the functional role of GOLGA6L10 in Golgi apparatus. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is essential for Golgi apparatus organization and vesicle trafficking. The disruption of microtubules can lead to mislocalization and dysfunction of GOLGA6L10. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, leading to ER stress and potential Golgi apparatus malfunction. As a Golgi-associated protein, GOLGA6L10 may be inhibited due to the disruption of ER-Golgi trafficking. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor that blocks dynamin-dependent endocytosis, which can interfere with vesicle trafficking from the Golgi, thereby indirectly inhibiting GOLGA6L10 function. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic acid induces ER stress and can lead to Golgi apparatus fragmentation, which could compromise the function of GOLGA6L10. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits Golgi alpha-mannosidase II, leading to misprocessing of N-linked oligosaccharides and disruption of Golgi function, potentially affecting GOLGA6L10. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
Exo2 is an exocyst complex inhibitor, impairing vesicle tethering at the plasma membrane. This can lead to downstream effects on Golgi apparatus function and thereby inhibit GOLGA6L10. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID 1067700 is an inhibitor of sec7 domain-containing proteins, which are involved in trafficking and secretion processes through the Golgi. Inhibition of these proteins can indirectly affect GOLGA6L10 function by disturbing Golgi-dependent processes. | ||||||